Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discovery Group Plc LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 184.50 184.50 185.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 58.3 -11.5 -3.1 - 291

Horizon Discovery Share Discussion Threads

Showing 1376 to 1400 of 1475 messages
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
DateSubjectAuthorDiscuss
12/8/2020
13:44
Agree. But I think we are blind to timelines. When will the application be submitted? I have seen the approval happen quickly thereafter (ie GAN was around one month).
wilmot666
12/8/2020
13:42
Got to get that US listing sorted!
carpingtris
04/8/2020
18:06
Hi all. This was announced today (informal channels not RNS) hTtps://www.cambridgenetwork.co.uk/news/horizon-discovery-introduces-single-cell-rnaseq-linked-crispr-screening-service
pireric
03/8/2020
17:50
Treeshake today?
carpingtris
03/8/2020
10:08
For my sins I have added at 150m market cap levels as i expect a bounce off here again. This drop is made of air. 30000 shares is costing me 100p and over. Mad
solooiler
01/8/2020
18:24
Yes. Now the covid first half is out of the way the news flow will be around listing progress in the next couple of months I hope which will rev the engine and get investors scrambling to get involved. Here are some annual report quotes In particular, the Board believes that the U.S. capital markets offer Horizon a larger pool of capital and a broader and deeper investor base in the biotechnology and life science tools sectors, both of which we believe would provide additional trading liquidity in our ordinary shares. Furthermore, listing in the U.S. would allow the Group to accelerate its ‘investing for growth’ strategy which could support further growth in shareholder value. With approximately 50% of our shares already held by U.S. investors at the time of writing, this is a timely move and one the Board has had under review for a considerable time. Q. Is that what is behind the proposed secondary listing in the U.S.? A. Partly. Our Board and advisers firmly believe that the U.S. capital markets would offer Horizon a larger pool of capital and a broader and deeper investor base. Any proceeds raised by the listing process would also allow us to accelerate our ‘investing for growth’ strategy. Q. What sort of reception have you had so far in the U.S.? A. It has been very encouraging. There has been a lot of interest in what we are doing and the feedback suggests that our equity story would have a strong resonance in the U.S. market once we are ready to launch.
solooiler
31/7/2020
10:37
I strong suspect management agree with you and that is why they are moving ahead with the US listing. GAN was another of my holdings which had to move to the Nasdaq to get a realistic valuation.
wilmot666
31/7/2020
10:22
How long until SOMEONE just takes HRZD out. Investors in England dont know what they are valuing. A great British science company that is barely moving because we are a grumbly bunch It is on less than 3 times sales and these things normally trade on 7x and more! Get that nasdaq listing sorted ASAP
solooiler
30/7/2020
10:53
Panmure upgraded to buy today with 158p targt hxxps://thefly.com/landingPageNews.php?id=3134976&headline=HZNQF-Horizon-Discovery-upgraded-to-Buy-from-Hold-at-Panmure-Gordon
solooiler
30/7/2020
07:36
No and they're not allowed to talk about it for regulatory purposes but the process seems to take about a month from when they fill out the f-1 foreign issuer form or at least thats how long it took with renalytix which i hold
solooiler
30/7/2020
07:20
I'm waiting for it to be added to their website. Any indication on US listing timelines?
wilmot666
29/7/2020
22:38
That webinar was a hard slog
the stigologist
29/7/2020
20:02
Trading update: Horizon expects to report half year 2020 revenues of approximately GBP22.4 million (HY 2019: GBP26.1 million, c. -13.9%)(1), approximately GBP22.0 million (c. -15.5%) on a constant currency basis. The change was largely due to the rapid reduction of academic research work caused by the COVID-19 pandemic impacting the Group's Research Reagents business unit and was broadly in line with Board expectations. The greatest impact was seen in the second quarter of 2020, most notably in April. This was then followed by a period of sustained recovery, which resulted in large parts of the business regaining momentum and returning towards 2019 levels of revenue by the end of June 2020. Gross margin from continuing operations (1) is expected to be approximately 66.0% (HY 2019: 71.2%). The margin decline is primarily due to the impact of COVID-19 on manufacturing costs and additional provisioning for aged inventory. Adjusted EBITDA is expected to be a loss of GBP4.6 million (HY 2019: GBP0.0 million(1) ). The Group's cash position was bolstered by a successful Placing in April 2020, which raised GBP6.9 million in gross proceeds, and was further strengthened by the implementation of enhanced cash control measures implemented in April. Taking this into account, the Group had cash and cash equivalents of GBP23.6 million as of 30 June 2020 (HY 2019: GBP24.8 million; FY 2019: GBP18.8 million). The Group's strong balance sheet provides financial flexibility to ensure operational delivery and continued strategic investment to fully benefit from market recovery. Terry Pizzie, Chief Executive Officer of Horizon Discovery , commented: "Thanks to the fantastic efforts of our staff, we have continued to operate effectively throughout the crisis and have built stronger and deeper relationships with our biopharma customers based on our ability to add value in difficult conditions. Our customers have increasingly adopted outsourcing as a solution to their own business challenges and we have become recognised as an invaluable long-term partner. "We expect the trend for increased outsourcing to continue, for these relationships to endure and facilitate high level access within our biopharma customer base that will help lay the foundations for commercialising our new high growth areas. "We are encouraged by our H2 2020 prospects and look forward to the remainder of the year with optimism and confidence about the Group's strategy and prospects." https://uk.advfn.com/stock-market/london/horizon-discovery-HZD/share-news/Horizon-Discovery-Group-plc-Half-Year-Trading-Upda/82945153
rambutan2
28/7/2020
10:47
Horizon Disovery will be presenting at the Proactive One2One Virtual Forum taking place on Thursday 30th July from 6pm. For details and registration, click here: https://tinyurl.com/y3qe3t4y
aim_trader
28/7/2020
03:20
Wed 3pm: htTps://horizondiscoveryplc.com/wp-content/uploads/2020/07/HZD-Capital-Markets-Webinar-Dial-in-details-24July2020.pdf
rambutan2
23/7/2020
11:09
Thanks, but you'd only see that if you logged on here which I certainly don't do every day, so how do ADVFN get it a day before I get the alert from Investegate?
bouleversee
23/7/2020
10:58
There on the News section on this very page. 'Top near headers'
carpingtris
23/7/2020
10:10
I have just rec'd the RNS you were talking about yesterday from Investegate, along with Melrose's trading statement, another one giving me a huge loss. How do you get them a day earlier?
bouleversee
23/7/2020
09:56
Big volume around 110 this morning, sells showing on my simple trades screen but still apparently well bid.
srichardson8
22/7/2020
22:40
Many thanks for digging that up. I rather thought that might be the case, in which case I hope they get taken over for a large profit; at present I am showing a large loss. Silly, really, to buy a non-div. paying share for the AIM benefit. Might just as well give it away in the first place. I'm unlikely to live another 7 years, though that rule might also be changed. Past caring, really. Should they get back to what I paid, I might just sell and spend the proceeds.
bouleversee
22/7/2020
20:45
Looks likely a no... htTps://www.sharesmagazine.co.uk/article/avoid-inheritance-tax-with-aim-stocks
rambutan2
22/7/2020
20:36
True.There certainly isn't the same motivation to buy them but I'd still like to know the current situation.
bouleversee
22/7/2020
20:18
I wouldn't bet on IHT exemption for AIM shares being around for that much longer. The Chancellor needs to raise tax.
rambutan2
22/7/2020
17:34
I'm sure they will but will the UK listing still qualify for IHT exemption as an AIM share?
bouleversee
22/7/2020
17:03
They might keep a dual listing?
carpingtris
Chat Pages: 59  58  57  56  55  54  53  52  51  50  49  48  Older
ADVFN Advertorial
Your Recent History
LSE
HZD
Horizon Di..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 05:26:26